This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Modified-release hydrocortisone (DuoCort) for adrenal insufficiency

< Back

Modified-release hydrocortisone (DuoCort) for adrenal insufficiency


Endocrine, Nutritional and Metabolic

May 2010

Modified-release hydrocortisone (DuoCort) combines rapid with extended-release hydrocortisone, a modified synthetic derivative of the naturally occurring hormone cortisol. Hydrocortisone binds to the glucocorticoid receptor thus mimicking the natural action of cortisol. Modified-release hydrocortisone is intended for the long-term treatment of AI as a substitute for current glucocorticoid replacement therapy and in clinical trials has been administered orally at 15-40mg once-daily. Most patients also received fludrocortisone at a median dose of 100mg daily.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts